Literature DB >> 20466939

Consistency of symptom clusters in advanced cancer.

Jordanka Kirkova1, Aynur Aktas, Declan Walsh, Lisa Rybicki, Mellar P Davis.   

Abstract

BACKGROUND: The reproducibility of symptom clusters (SCs) in different populations would support the validity of the cluster concept. Ideal approaches to cluster identification are unknown. The presence of a sentinel (most prevalent) symptom may reduce the number of symptoms in a comprehensive symptom assessment tool. The primary purpose was to assess consistency of SCs between 2 independent data sets. A secondary aim was to evaluate whether use of a sentinel symptom might abbreviate assessment but retain acceptable accuracy.
METHODS: An agglomerative hierarchical cluster analysis in 922 patients with advanced cancer identified 7 SCs. We conducted the same analysis on an additional 181 cancer patients to assess cluster consistency. The most prevalent symptom within each cluster was defined as the ''sentinel'' symptom. Positive predictive value (PPV) and negative predictive value (NPV) were calculated to assess ability of the sentinel symptom to predict other symptoms in the cluster.
RESULTS: Similar clusters were identified in both data sets, which included nausea/vomiting, neuropsychologic, and aerodigestive clusters. When the sentinel symptom was present, >50% nonsentinel symptoms in a cluster were present; when absent, <50% nonsentinel symptoms were identified. However, the range for PPV and NPV of the sentinel symptom to identify other symptoms in the cluster was 19% to 72% and 41% to 95%, respectively.
CONCLUSIONS: Consistent SCs were found in 2 separate data sets with the same assessment tool and statistical analysis. These findings support the statistical and clinical validity of the cluster concept through consistency between different populations. The nausea/vomiting, neuropsychologic, and aerodigestive clusters may be reliable for use in assessment. The presence or absence of a sentinel symptom in each cluster did not predict the presence or absence of other symptoms in the cluster. Sentinel symptoms are inadequate to assess symptom burden.

Entities:  

Mesh:

Year:  2010        PMID: 20466939     DOI: 10.1177/1049909110369869

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  8 in total

Review 1.  Advancing Symptom Science Through Symptom Cluster Research: Expert Panel Proceedings and Recommendations.

Authors:  Christine Miaskowski; Andrea Barsevick; Ann Berger; Rocco Casagrande; Patricia A Grady; Paul Jacobsen; Jean Kutner; Donald Patrick; Lani Zimmerman; Canhua Xiao; Martha Matocha; Sue Marden
Journal:  J Natl Cancer Inst       Date:  2017-01-24       Impact factor: 13.506

Review 2.  The pathophysiology of cancer-related fatigue: current controversies.

Authors:  C M O'Higgins; B Brady; B O'Connor; Declan Walsh; R B Reilly
Journal:  Support Care Cancer       Date:  2018-06-30       Impact factor: 3.603

3.  Stability of symptom clusters and sentinel symptoms during the first two cycles of adjuvant chemotherapy.

Authors:  Sun Young Rha; Mira Park; Jiyeon Lee
Journal:  Support Care Cancer       Date:  2018-08-17       Impact factor: 3.603

Review 4.  Cancer Symptom Cluster Management.

Authors:  Kristine L Kwekkeboom
Journal:  Semin Oncol Nurs       Date:  2016-10-24       Impact factor: 2.315

5.  Characterizing distress, the 6th vital sign, in an oncology pain clinic.

Authors:  A Waller; S L Groff; N Hagen; B D Bultz; L E Carlson
Journal:  Curr Oncol       Date:  2012-04       Impact factor: 3.677

Review 6.  Fighting insomnia and battling lethargy: the yin and yang of palliative care.

Authors:  Mellar P Davis; Harold Goforth
Journal:  Curr Oncol Rep       Date:  2014-04       Impact factor: 5.075

7.  Treatment-related symptom severity and occurrences among oncology adults in Australia.

Authors:  Violeta Lopez; Phoebe Williams; David Larkin
Journal:  Asia Pac J Oncol Nurs       Date:  2015 Jul-Sep

8.  A prospective exploration of symptom burden clusters in women with breast cancer during chemotherapy treatment.

Authors:  Maria Browall; Yvonne Brandberg; Salmir Nasic; Per Rydberg; Jonas Bergh; Andreas Rydén; Hanjing Xie; Irene Eriksson; Yvonne Wengström
Journal:  Support Care Cancer       Date:  2016-12-15       Impact factor: 3.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.